Abstract: Barcelona Clinic Liver Cancer (BCLC) has been recommended as the best staging system and treatment guideline for hepatocellular carcinoma by European Association for the Study of the Liver (EASL) and the American Association for the Study of the Liver Disease (AASLD), assuming that hepatectomy is only for patients in stage 0 or A of BCLC rather than for patients in stage B or C. Recent retrospective studies show that the longterm survival rate of patients in stage B or C receiving partial hepatectomy is higher than Transhepatic Arterial Chemotherapy and Embolization (TACE) and systemic treatment, leading to controversies among international scholars. Therefore, whether or not partial hepatectomy as the treatment method for patients in stage 0 or A of BCLC need further researches to determine.